StreetInsider.com News Articles

Aspen Neuroscience prices IPO at $15 per share on Nasdaq

Thu, 29 Oct 2026 22:12:42 -0400

Aspen Neuroscience, Inc. (Nasdaq: ASPE), a clinical-stage biotechnology company developing cell therapies for Parkinson's disease, priced its initial public offering of 9,375,000 shares of common stock at $15.00 per share, according to a press release.

The company expects gross proceeds of approximately $140.6 million before deducting underwriting discounts, commissions, and other offering expenses. Aspen has also granted underwriters a 30-day option to purchase up to an additional 1,406,250 shares at the public offering price, less underwriting discounts and commissions.

Shares were expected to begin trading on The Nasdaq Global Select Market on Oct. 30, 2026, with the offering expected to close on

Aspen Neuroscience prices IPO at $15 per share on Nasdaq

Thu, 29 Oct 2026 22:12:42 -0400

Shares were expected to begin trading on The Nasdaq Global Select Market on Oct. 30, 2026, with the offering expected to close on

Aspen Neuroscience Announces Pricing of Initial Public Offering

Thu, 29 Oct 2026 22:12:00 -0400

SAN DIEGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Aspen Neuroscience, Inc. (Nasdaq: ASPE), a clinical-stage regenerative medicine biotechnology company developing autologous cell therapies for Parkinson’s disease (PD), today announced the pricing of its initial public offering of 9,375,000 shares of common stock at a price to the public of $15.00 per share. All of the shares of common stock are being offered by Aspen. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Aspen, are expected to be approximately $140.6 million. In addition, Aspen has granted the underwriters a

Aspen Neuroscience Announces Pricing of Initial Public Offering

Thu, 29 Oct 2026 22:12:00 -0400